Psoriasis vaccine - Immune Response BioPharma

Drug Profile

Psoriasis vaccine - Immune Response BioPharma

Alternative Names: IR-502; Zorcell

Latest Information Update: 08 Mar 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Immune Response Corporation
  • Class Vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Psoriasis

Highest Development Phases

  • Phase II Plaque psoriasis

Most Recent Events

  • 08 Mar 2016 Zorcell™ is still in phase IIb trials for Psoriasis in USA (IM, Injection)
  • 08 Mar 2016 Zorcell™ is available for licensing (
  • 04 Feb 2014 Phase-IIb development of Zorcell™ is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top